Connect Biopharma Completes Enrollment in Phase 2 Rademikibart Asthma Study

MT Newswires Live

Jun 17

Connect Biopharma (CNTB) has completed enrollment in its Phase 2 Seabreeze STAT asthma study evaluating rademikibart for acute asthma exacerbations, the company said Wednesday.

The randomized, placebo-controlled study enrolled 160 participants globally and is evaluating the safety and efficacy of the IL-4R alpha antibody as an adjunct to standard of care in patients with type 2 inflammation, the company said.

Connect Biopharma said it remains on track to complete enrollment in a related COPD study this month and expects to report topline asthma data in early September 2026.

Shares of the company were up 4.5% in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2644413357"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644413357\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644413357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644413357","market":"us","top_or_hot":-1,"title":"Connect Biopharma Completes Enrollment in Phase 2 Rademikibart Asthma Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> (CNTB) has completed enrollment in its Phase 2 Seabreeze STAT asthma study evaluating rademikibart for acute asthma exacerbations, the company said Wednesday.</p><p>The randomized, placebo-controlled study enrolled 160 participants globally and is evaluating the safety and efficacy of the IL-4R alpha antibody as an adjunct to standard of care in patients with type 2 inflammation, the company said.</p><p>Connect Biopharma said it remains on track to complete enrollment in a related COPD study this month and expects to report topline asthma data in early September 2026.</p><p>Shares of the company were up 4.5% in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Completes Enrollment in Phase 2 Rademikibart Asthma Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Completes Enrollment in Phase 2 Rademikibart Asthma Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-17 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> (CNTB) has completed enrollment in its Phase 2 Seabreeze STAT asthma study evaluating rademikibart for acute asthma exacerbations, the company said Wednesday.</p><p>The randomized, placebo-controlled study enrolled 160 participants globally and is evaluating the safety and efficacy of the IL-4R alpha antibody as an adjunct to standard of care in patients with type 2 inflammation, the company said.</p><p>Connect Biopharma said it remains on track to complete enrollment in a related COPD study this month and expects to report topline asthma data in early September 2026.</p><p>Shares of the company were up 4.5% in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTB","symbol_name":"康乃德生物医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644413357","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644413357","pubTimestamp":1781703088,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Connect Biopharma  has completed enrollment in its Phase 2 Seabreeze STAT asthma study evaluating rademikibart for acute asthma exacerbations, the company said Wednesday.The randomized, placebo-controlled study enrolled 160 participants globally and is evaluating the safety and efficacy of the IL-4R alpha antibody as an adjunct to standard of care in patients with type 2 inflammation, the company said.Connect Biopharma said it remains on track to complete enrollment in a related COPD study this month and expects to report topline asthma data in early September 2026.Shares of the company were up 4.5% in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTB":"康乃德生物医药","BK4139":"生物科技"},"translate_title":"Connect Biopharma完成Rademikibart哮喘2期研究的入组","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":1},"content_text":"Connect Biopharma (CNTB) has completed enrollment in its Phase 2 Seabreeze STAT asthma study evaluating rademikibart for acute asthma exacerbations, the company said Wednesday.The randomized, placebo-controlled study enrolled 160 participants globally and is evaluating the safety and efficacy of the IL-4R alpha antibody as an adjunct to standard of care in patients with type 2 inflammation, the company said.Connect Biopharma said it remains on track to complete enrollment in a related COPD study this month and expects to report topline asthma data in early September 2026.Shares of the company were up 4.5% in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}